First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Study Name | |
First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | |
ClinicalTrials.gov Identifier (if applicable) | |
NCT04526106 | |
Clinical Trial Category (check all that apply) | |
|
|
Study Center | |
Institution Name | |
Please see clinicaltrials.gov | |
Country | |
United States | |
Study Contacts | |
Principal Investigator | |
Please see clinicaltrials.gov | |
P.I. Phone | |
(339) 230-7475 | |
P.I. Email | |
ClinicalTrials@relaytx.com | |
Study Coordinator | |
Please see clinicaltrials.gov | |
Study Coordinator Phone | |
(339) 230-7475 | |
Study Coordinator Email | |
ClinicalTrials@relaytx.com | |
OVERVIEW – in layman’s terms (150 words max) | |
This clinical trial is studying the safety and effectiveness of an investigational drug for patients with Cholangiocarcinoma and other solid tumors that meet eligibility requirements. This investigational drug is a highly selective Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitor. Please refer to Clinicaltrials.gov for more information. | |
Enrollment | |
Ongoing | |
Study Start Date | |
09/01/2020 | |
Estimated Completion Date | |
10/01/2024 |